Innovations • Global Impact • In The News • Our People
Adjuvant formulations - a tipping point for global health?
Major milestones for advancing vaccines against tuberculosis and malaria were announced last month, all relying on adjuvant formulation technology. AAHI scientists share their practical and creative approach to adjuvant development to establish sustainable and resilient global health infrastructure.
The latest scientific breakthroughs at AAHI.
A Practical Approach to Vaccine Formulations - 5 Recommendations for New Adjuvant Development
Adjuvant formulations unlock vaccine potential to provide protection from some of the most complex diseases. AAHI scientists take a pragmatic and creative approach to vaccine formulation development to ensure equitable access.
AAHI scientists identify most stable dried formulation of TB vaccine candidate ID93+GLA-SE to eliminate cold chain requirements that hinder equitable access to vaccines in areas where the bacterium is most prevalent.
Researchers analysed the stability of various dried vaccine formulations of AAHI's ID93+GLA-SE tuberculosis vaccine candidate by applying temperature, mechanical, photochemical, and oxidative stress and then testing whether the vaccine still worked in mice. They determined that AAHI's vaccine can withstand prolonged exposure to such stresses.
Make your products accessible to those who need them most. Collaborate with AAHI.
Collaboration across communities.
Explore AAHI's different areas of impact.
Burkina Faso, Madagascar
Tropical disease transmitted by worms on verge of being curbed
Schistosomiasis is a complex target because the parasitic flatworm that causes the disease is long-lived and versatile, with an ever-mutating surface membrane that complicates immune responses. No vaccine exists to provide protection against this neglected tropical disease that has infected over 140 million people. A new schistosomiasis vaccine candidate that recently completed first-in-human clinical trials in Seattle, WA provides growing hope for protection. The candidate uses AAHI's GLA-SE adjuvant formulation. The vaccine candidate will be evaluated in clinical trails in Madagascar and Burkina Faso, where Schistosomiasis is endemic.
Help us make impossible vaccines possible.
NEWS WE FOLLOW
By Amy Maxmen
The Washington Post
Amy Maxmen discusses the challenges in sustaining efforts such as mRNA vaccine technology transfer hub initiative launched by the World Health Organization to share mRNA technology development and manufactruing worldwide.
AAHI is committed to simplifying RNA vaccine development by creating temperature stable vaccine technologies with sustainable, streamlined manufacturing processes to establish efficient healthcare infrastructure worldwide.
"The pandemic showed us that you can't depend on others when the world is competing for a resource. We need to make our own." - Sotriis Missailidis, director of innovation at the government research institute Bio-Manguinhos/Fiocruz, whom AAHI partnered with to develop vaccines against hookworm and schistosomiasis.
Collaboration across communities.
Explore our different areas of impact.
At this year's Military Health System Research Symposium, the DoD premier scientific meeting to discuss medical countermeasures, Emily Voigt, PhD, Principal Scientist and leader of AAHI's RNA vaccine platform, will present the promising results of AAHI's research on:
1) The intranasal administration of AAHI's RNA vaccine technologies to provide enhanced protection against viral respiratory infection and transmission of disease
2) preclinical evaluation of AAHI's yellow fever RNA vaccine candidate slated to enter clinical trials in 2024 with the support of the NIH
Openings and Opportunities
The Scientist I/II/Senior Scientist will be responsible for broadening the applications of AAHI's RNA vaccine platform to a wide range of infectious disease and oncology targets and will lead a growing, multi-level, early development team to bring novel RNA vaccine candidates to the initiation of Phase 1 clinical trials.
The Associate/Staff Scientist will be responsible for directing the in vivo mouse immunology studies on the RNA team, providing support to conduct in vivo aspects of product stability and release testing studies for AAHI's Product Development and GMP teams as necessary.
Learn more about our formulation technology
We partner with biotech leaders to develop vaccines and more.
See how our formulations are being used.